Clinical trial · Interventional
Allergy Delabeling in Antibiotic Stewardship - Intervention
Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention
NCT07133074CI-TRIAL-00115095RENEW-INrecruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Beta Lactam Allergy | — | UNRESOLVED | — |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EMR Review | Other | — | UNRESOLVED |
| RENEW-IN Algorithm for assessment of a beta-lactam intervention | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Patients who enroll in the RENEW intervention
- description
- Patients who agree to actively participate in the RENEW intervention designed to identify opportunities to have the beta lactam allergy label removed from their electronic medical record.
- interventionNames
- Diagnostic Test: RENEW-IN Algorithm for assessment of a beta-lactam intervention
- type
- OTHER
- label
- Patients hospitalized with a hematologic malignancy in the time period prior to the intervention
- description
- Patients who are hospitalized with a hematologic malignancy who would meet the inclusion criteria for the intervention but who were not approached since they were hospitalized in the time period prior to introduction of the intervention. These patients will be used as a control group. Charts for these patients will be retrospectively reviewed and data will be extracted for analysis of the primary and secondary outcomes.
- interventionNames
- Other: EMR Review
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service * reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem) Exclusion Criteria: * patients with a history of severe cutaneous adverse reaction * patients with a history of Stevens-Johnson syndrome * patients with a history of toxic epidermal necrolysis * patients with a history of drug-induced exfoliative dermatitis * patients with a history of drug reaction with eosinophilia and systemic symptoms * patients with a history of acute generalized exanthematous pustulosis
References
Publications (0)
Data not yet available
No reference posted for this study.